Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is often associated with pathological conditions, such as
 insulin resistance (IR), type 2 diabetes (DM2), obesity and it has potentially increased risk
 for cardiovascular disease (CVD). Of note, risk factors for CVD including dyslipidaemia,
 hypertension, oxidative stress and inflammation are associated with PCOS. The investigators
 want to evaluate the effects of two different types of E/P therapy on cardiovascular risk in
 PCOS.
PCOS is the most common female endocrinopathy in reproductive age. This syndrome is a
 heterogeneous condition characterized by several symptoms and clinical signs related to
 reproductive, cardiometabolic and psychological disorders.We recently demonstrated that young
 PCOS women show an expansion of an unusual T-cell population with proinflammatory functions,
 identified by CD4+CD28null T lymphocytes . Of note, this T subpopulation has been found to be
 expanded in patients with unstable angina, type 2 diabetes (DM2), in absence of clinical
 evidence of CVD 12, and has been recently associated to recurrent coronary instability .Based
 on the above mentioned evidences, the aim of the present study is to evaluate the effects of
 DRPS/EE alone versus metformin alone versus DRPS/EE plus metformin on the CD4+CD28null T
 cells frequency and on endocrino-metabolic parameters, in hyperinsulinemic PCOS patientsTo
 evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) and NOMAC-valerate
 estardiol on some cardiovascular risk factors in PCOS patients.
Inclusion Criteria:

 -  patients with PCOS aged 18-35 years

 Exclusion Criteria:

 -  chronic or acute inflammatory disease

 -  cancer

 -  autoimmune disease

 -  treatment with clomiphene citrate

 -  antiandrogens

 -  drugs to control appetite or insulin-sensitizing drugs (metformin, pioglitazone and
 rosiglitazone) during the last 6 months prior to our evaluation, DM2, hypertension,
 major surgery in the last 3 months or other hormonal dysfunctions (hypothalamic,
 pituitary, thyroidal, or adrenal causes)